Back to Search
Start Over
Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma.
- Source :
-
HPB . Aug2014, Vol. 16 Issue 8, p758-767. 10p. - Publication Year :
- 2014
-
Abstract
- Background Despite the increasing annual incidence of hepatocellular carcinoma ( HCC) in the USA, now estimated at 2.7 cases per 100 000 population, only a small proportion of patients receive treatment and 5-year survival rates range from 9% to 17%. Objectives The present study examines the effects of multimodal treatment on survival in a mixed-stage HCC cohort, focusing on the impact of radical therapy in patients with Barcelona Clinic Liver Cancer ( BCLC) stage B disease. Methods A retrospective review of the medical records of 254 patients considered for HCC treatment between 2003 and 2011 at a large tertiary referral centre was conducted. Results A total of 195 (76.8%) patients were treated with a median of two liver-directed interventions. Median survival time was 16 months. In proportional hazards analysis, radiofrequency ablation ( RFA) and resection were associated with significantly improved 1- and 5-year survival among patients with BCLC stage 0-A disease. In patients with BCLC stage B disease, RFA conferred a survival benefit at 1 year and resection was associated with significantly improved survival at 5 years. Conclusions As one of few studies to track the complete course of sequential HCC therapies, the findings of the present study suggest that HCC patients with intermediate-stage ( BCLC stage B) disease may benefit from aggressive interventions not currently included in societal guidelines. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1365182X
- Volume :
- 16
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- HPB
- Publication Type :
- Academic Journal
- Accession number :
- 97012342
- Full Text :
- https://doi.org/10.1111/hpb.12214